Safety and efficacy of purified Vero cell rabies vaccine given intramuscularly and intradermally. (Results of a prospective randomized trial).
OBJECTIVE
To determine adverse reactions as a result of pre- and post-exposure rabies vaccination, using the conventional intramuscular, and reduced dose intradermal regimens and purified Vero cell rabies vaccine.


METHODS
A prospective and randomized study of patients exposed to rabies and of subjects in need of pre-exposure rabies vaccination.


METHODS
A metropolitan rabies control center in a canine rabies endemic country.


METHODS
1198 subjects were recruited between May, 1994 and March, 1996. They were divided into four groups. Patients with suspected or proven rabies exposures were given the vaccine intramuscularly using the conventional regimen, or intradermally using the World Health Organization approved Thai Red Cross schedule. Human or equine rabies immune globulin was administered where indicated. Pre-exposure and post-exposure vaccine recipients were divided randomly into two groups each and given the vaccine either by the intramuscular or intradermal schedules.


METHODS
All local and systemic adverse reactions were recorded and statistically analyzed.


RESULTS
Pruritus at injection sites was the only significant local reaction. It was more common in the intradermal groups. Low-grade fever, the only significant adverse systemic event, was more common in the intramuscular groups and was noted in 8% of all subjects. Eighty-four patients bitten by proven rabid animals were found to be alive and well 3 years later. Forty-four of these had received the intramuscular and 40 the intradermal postexposure regimens with human or equine immune globulin injected into wounds on the first day of treatment.


CONCLUSIONS
Purified Vero cell rabies vaccine is safe, carries a very low adverse reaction rate and is effective in preventing rabies in severely exposed subjects when used with human or equine rabies immune globulin.
Jaiiaroensup
W
W
Queen Saovabha Memorial Institute, (WHO Collaborating Center for Research in Rabies), Chulalongkorn University, Bangkok, Thailand.
Lang
J
J
Thipkong
P
P
Wimalaratne
O
O
Samranwataya
P
P
Saikasem
A
A
Chareonwai
S
S
Yenmuang
W
W
Prakongsri
S
S
Sitprija
V
V
Wilde
H
H
D000328:Adult; D000818:Animals; D002522:Chlorocebus aethiops; D004285:Dogs; D005260:Female; D006801:Humans; D007271:Injections, Intradermal; D007273:Injections, Intramuscular; D008297:Male; D011446:Prospective Studies; D011818:Rabies / Q000517:prevention & control*; D011819:Rabies Vaccines / Q000008:administration & dosage* / Q000009:adverse effects*; D014709:Vero Cells
D011819:Rabies Vaccines